• Connect with us
    • Information
      • About Us
      • Contact Us
      • Careers
      • Partnerships
      • Advertise With Us
      • Authors
      • Browse Topics
      • Events
      • Disclaimer
      • Privacy Policy
    • Australia
      North America
      World
    Login
    Investing News NetworkYour trusted source for investing success
    • North America
      Australia
      World
    • My INN
    Videos
    Companies
    Press Releases
    Private Placements
    SUBSCRIBE
    • Reports & Guides
      • Market Outlook Reports
      • Investing Guides
    • Button
    Resource
    • Precious Metals
    • Battery Metals
    • Base Metals
    • Energy
    • Critical Metals
    Tech
    Life Science
    Medical Device Market
    Medical Device News
    Medical Device Stocks
    • Medical Device Market
    • Medical Device News
    • Medical Device Stocks
    medical device investing

    Profound Medical Corp. Announces Fourth Quarter and Full Year 2017 Financial Results

    Gabrielle Lakusta
    Mar. 27, 2018 08:53AM PST
    Medical Device Investing

    Profound Medical (TSX-V:PRN) the only company to provide a therapeutics platform that provides the precision of real-time Magnetic Resonance imaging combined with the safety and ablation power of directional (inside-out) and focused (outside-in) ultrasound technology for the incision-free ablation of diseased tissue, today reported financial results for the fourth quarter and full year ended December …

    Profound Medical (TSX-V:PRN) the only company to provide a therapeutics platform that provides the precision of real-time Magnetic Resonance imaging combined with the safety and ablation power of directional (inside-out) and focused (outside-in) ultrasound technology for the incision-free ablation of diseased tissue, today reported financial results for the fourth quarter and full year ended December 31, 2017.

    As quoted in the press release:

    “2017 was truly a transformative year for Profound,” said Arun Menawat, Profound’s CEO. “With the growing success of the pilot commercial launch of TULSA-PRO® in Europe, combined with the acquisition of Philips’ Sonalleve® business, Profound made the leap from a development-stage medical device company to a platform company focused on growth. Through the last financing, we now also have the financial resources required to continue to further drive clinical adoption of TULSA-PRO® in Europe, advance development of the technology toward successful commercialization in the United States, and execute our commercial plans for the Sonalleve® business.”

    Click here to read the full press release.

    europemedical device companyfinancial resultsmedical device investingunited states
    The Conversation (0)

    Go Deeper

    AI Powered
    Stethoscope connected to a phone with medical data overlay.

    Top 5 Small-cap Medical Device Stocks (Updated January 2025)

    Medical pills branded with Canadian flag.

    Canadian Pharma Stocks: 5 Biggest Companies

    Latest News

    Outlook Reports

    Resource
    • Precious Metals
      • Gold
      • Silver
    • Battery Metals
      • Lithium
      • Cobalt
      • Graphite
    • Energy
      • Uranium
      • Oil and Gas
    • Base Metals
      • Copper
      • Nickel
      • Zinc
    • Critical Metals
      • Rare Earths
    • Industrial Metals
    • Agriculture
    Tech
      • Artificial Intelligence
      • Cybersecurity
      • Gaming
      • Cleantech
      • Emerging Tech
    Life Science
      • Biotech
      • Cannabis
      • Psychedelics
      • Pharmaceuticals

    Featured Medical Device Investing Stocks

    Cardiex Limited

    CDX:AU
    More featured stocks

    Browse Companies

    Resource
    • Precious Metals
    • Battery Metals
    • Energy
    • Base Metals
    • Critical Metals
    Tech
    Life Science
    MARKETS
    COMMODITIES
    CURRENCIES
    ×